Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment Information

v3.10.0.1
Segment Information
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Segment Reporting Disclosure Segment Information
We have two primary types of customers, Clinical and Pharma.  Our Clinical customers include community based pathology practices, oncology groups, hospitals and academic centers.  Our Pharma customers include pharmaceutical companies to whom we provide testing and other services to support their studies and clinical trials.
We have presented the financial information reviewed by the Chief Operating Decision Maker (“CODM”) including revenues, cost of revenue and gross margin for each of our operating segments.  The segment information presented in these financial statements has been conformed to present segments on this revised basis for all prior periods.  Balance sheet accounts are not presented at the segment level as that information is not used by the CODM.  
The following table summarizes segment information for the years ended December 31, 2018, 2017 and 2016 (in thousands).  
  For the Years Ended December 31,
  2018 2017
(as adjusted)
2016
(as adjusted)
Net Revenues:      
Clinical Services $ 241,873  $ 213,097  $ 210,159 
Pharma Services 34,868  27,154  21,649 
Total Revenue $ 276,741  $ 240,251  $ 231,808 
Cost of Revenue:
Clinical Services $ 128,297  $ 121,785  $ 120,437 
Pharma Services 21,179  16,510  13,267 
Total Cost of Revenue $ 149,476  $ 138,295  $ 133,704 
Gross Margin:
Clinical Services $ 113,576  $ 91,313  $ 89,722 
Pharma Services 13,689  10,643  8,382 
Total Gross Margin $ 127,265  $ 101,956  $ 98,104